Tenaya Therapeutics Names Eric Hyllengren CFO Amid Clinical Advancements
Event summary
- Eric Hyllengren appointed CFO of Tenaya Therapeutics, effective July 13, 2026.
- Hyllengren brings over two decades of biotech finance experience, including roles at Zura Bio and Atara Biotherapeutics.
- Tenaya's pipeline includes three clinical-stage candidates targeting heart disease.
- Hiro Higa, SVP of Finance, to retire in Q3 2026 but will consult during transition.
The big picture
Tenaya Therapeutics' appointment of Eric Hyllengren as CFO underscores its push toward pivotal clinical trials for heart disease therapies. The move comes amid a broader industry shift toward genetic medicines, with Tenaya positioning itself to capitalize on this trend through targeted acquisitions and strategic financings. Hyllengren's experience in cell and gene therapy financing will be critical as the company navigates the capital-intensive path to market.
What we're watching
- Clinical Milestones
- How Tenaya's advancement of TN-201, TN-401, and TN-301 toward pivotal trials will impact its valuation.
- Capital Allocation
- Whether Hyllengren can optimize financial strategy to support Tenaya's ambitious pipeline.
- Leadership Transition
- The pace at which Hyllengren integrates and addresses post-IPO financial challenges.
Related topics